Thygeson’s Disease: Symptoms, Diagnosis, and Treatment

Thygeson’s disease, formally known as Thygeson’s superficial punctate keratitis (TSPK), is an uncommon inflammatory condition of the cornea marked by recurring episodes of irritation, light sensitivity, and tearing, caused by distinctive granular lesions scattered across the corneal surface. The condition tends to wax and wane over years, and while it rarely threatens long-term vision, its chronic, relapsing nature can significantly disrupt daily life. What makes it particularly frustrating for patients and clinicians alike is that nobody has definitively pinned down what causes it, and getting the right diagnosis can take months or longer.

What Symptoms Feel Like During a Flare

The hallmark complaints during an active episode are photophobia (sensitivity to light), tearing, a gritty foreign-body sensation, and blurred vision.¹ Photophobia is frequently the most bothersome of these, driving patients to squint or avoid bright environments. A pediatric case series found photophobia in the vast majority of patients, with foreign-body sensation and itching close behind.² The discomfort can range from mildly annoying during quiet flares to genuinely debilitating during active ones, when even indoor lighting feels harsh.

Between episodes, many people feel perfectly fine. The cornea may look clear to the naked eye, and symptoms can vanish entirely for weeks or months before returning. This on-and-off pattern is a defining characteristic of TSPK. It also contributes to diagnostic delay, because the condition may not be active during a scheduled eye appointment.

What an Eye Doctor Sees on Exam

The clinical picture that sets TSPK apart from other forms of keratitis is the appearance of the corneal lesions themselves. Under slit-lamp examination, the cornea shows multiple small, grayish-white, granular-looking spots sitting within the epithelium, the outermost layer of the cornea.³ These lesions are slightly elevated, giving them a raised texture that an experienced clinician can recognize.⁴ They tend to cluster centrally on the cornea and usually affect both eyes, though one eye may be worse than the other at any given time.

A crucial detail for diagnosis is what the eye does not show. Unlike many other causes of keratitis, TSPK involves minimal or no conjunctival redness or inflammation.³ This is unusual: most corneal infections and inflammatory conditions produce an obviously red, angry-looking eye. With TSPK, the eye may look deceptively calm while the patient reports significant discomfort. That mismatch between a relatively quiet-looking eye and disproportionate symptoms is itself a diagnostic clue.

More detailed imaging with confocal microscopy, which allows clinicians to examine the cornea at a cellular level, reveals additional changes beneath the surface. Researchers have documented irregular nerve fibers in the layer just above Bowman’s membrane, along with generalized haze in the front part of the stroma and keratocytes (corneal cells) with abnormally reflective, irregularly shaped nuclei.⁵ Langerhans cells, which are immune cells that normally patrol the corneal surface, have been spotted scattered through the basal layer of the epithelium in TSPK patients.⁶ Their presence hints at an active immune process going on in what should be an immunologically quiet tissue.

Why the Cause Remains a Mystery

Decades after the condition was first described, the underlying cause of TSPK is still debated. The leading hypothesis for many years was that a virus might be responsible. The lesions look somewhat similar to those caused by adenovirus or herpes viruses, and the relapsing-remitting pattern is reminiscent of viral reactivation. However, laboratory testing has consistently failed to find the usual suspects. A study that used highly sensitive molecular testing on corneal epithelial samples from patients with active TSPK found no evidence of herpes simplex virus types 1 or 2, varicella-zoster virus, or adenovirus in any of the samples tested.⁷ That doesn’t conclusively rule out a viral trigger, since some unknown or less common virus could still be involved, but the most obvious candidates have been essentially cleared.

The alternative explanation, and the one gaining more traction, centers on the immune system. Researchers have noted a link between TSPK and a particular genetic marker called HLA-DR3, which is associated with a range of autoimmune conditions. The fact that immunosuppressive drugs like cyclosporine and tacrolimus work well for TSPK lends further weight to the idea that T-cell-mediated immune activity drives the disease.⁸ It is possible that both theories are partially right: an initial viral insult might trigger an immune response in genetically susceptible individuals, and that immune process then takes on a life of its own. But for now, no single explanation has won out, and the honest answer is that the cause remains unknown.

Getting the Diagnosis Right

There is no blood test or biopsy that confirms TSPK. The diagnosis is made clinically, based on the characteristic pattern of bilateral, elevated, intraepithelial corneal lesions in the absence of significant conjunctival inflammation, along with the typical symptoms and a chronic relapsing course. This makes TSPK essentially a diagnosis of exclusion: an ophthalmologist needs to rule out other causes of superficial punctate keratitis before settling on it.³

The list of conditions that can mimic TSPK is long and includes dry eye disease, viral keratitis (especially adenoviral or herpes simplex), allergic keratoconjunctivitis, contact-lens-related keratitis, and certain corneal dystrophies. In practice, misdiagnosis is common. A pediatric cohort study found that six out of 24 children initially received incorrect diagnoses, including post-viral subepithelial infiltrates, allergic keratoconjunctivitis, and herpes simplex keratitis, with a mean diagnostic delay of about two and a half months. In one case, the correct diagnosis took ten years.²

Misdiagnosis matters because the wrong treatment can make things worse. Antibiotics and antiviral eye drops, which are among the first things prescribed for eye irritation in primary care, are ineffective against TSPK.⁴ A patient who keeps returning with the same symptoms despite rounds of antibiotic or antiviral drops should prompt a clinician to reconsider the diagnosis.

Corticosteroid Drops as First-Line Treatment

Topical corticosteroid eye drops remain the main treatment for active TSPK flares. Low-potency steroids like fluorometholone are typically tried first. During a flare, steroid drops can quickly reduce the corneal lesions and relieve symptoms. In a pediatric series of 15 children, all received topical fluorometholone initially, and about 80% responded well.⁹ The typical approach is to use drops at a higher frequency during a flare, then taper gradually over several weeks.

The trouble is that TSPK is a chronic, relapsing condition, and many patients end up needing repeated or prolonged steroid courses. Long-term topical corticosteroid use carries real risks: elevated eye pressure (which can damage the optic nerve, similar to glaucoma) and cataract formation.¹⁰ Some patients are “steroid responders,” meaning their intraocular pressure climbs faster than average on these medications. In the pediatric cohort mentioned above, about 12.5% of children developed elevated eye pressure while on steroid drops.² For a disease that can last a decade or more, this is a serious concern and the main reason clinicians look for steroid-sparing alternatives.

Steroid-Sparing Alternatives

For patients who relapse frequently, respond poorly to steroids, or face mounting side effects, immunomodulatory agents have emerged as valuable alternatives. Cyclosporine eye drops work by dampening the local immune response on the corneal surface. Bandage contact lenses can also be used alongside medication to physically shield the cornea and reduce irritation during flares.¹¹ In the pediatric study from Eye journal, adding cyclosporine significantly reduced how much steroid the children needed each week.⁹

Tacrolimus, another immunomodulatory drug, has been gaining attention as a steroid-sparing option. Applied as a topical ointment, it targets the same T-cell-driven inflammation that seems central to the disease. Research on tacrolimus at a low concentration found it safe and effective at reducing corneal inflammation in patients who didn’t respond adequately to conventional treatments, and it avoided the intraocular pressure concerns that come with steroids.¹² A separate study using a slightly different concentration reported that all patients improved symptomatically within about three days of starting treatment, with no side effects noted.¹³ A more recent case report has explored an even higher-concentration formulation and suggested it could contribute to prolonged symptom control, which is especially appealing for younger patients who face decades of potential steroid exposure.¹⁴

It is worth noting that tacrolimus ointments used for TSPK are often dermatological formulations being repurposed for ocular use, since dedicated ophthalmic preparations are not widely available. This off-label use is guided by clinical experience rather than large-scale trials, and patients using it should be monitored by an ophthalmologist familiar with the approach.

TSPK in Children

Although TSPK can appear at any age, pediatric cases present distinct challenges. Young children may not articulate symptoms clearly, and the condition can be mistaken for allergic eye disease or infection. In one cohort, the youngest patient was just two years old, and boys outnumbered girls roughly two to one.² In another series, the average age at presentation was around eight, and all children had bilateral disease.⁹

Diagnosing TSPK in children sometimes requires corneal scraping to rule out infectious causes, which in young patients often has to be done under general anesthesia. In the pediatric cohort reported in Eye, four children needed examination under anesthesia for corneal scraping, and two of those turned out to have a completely different condition, a corneal dystrophy, rather than TSPK.⁹ This underscores the importance of a thorough workup when the initial response to treatment is not what you would expect.

Treatment follows the same general approach as in adults: low-potency steroids first, with cyclosporine added to reduce steroid burden over time. The steroid risks are especially worrisome in children, because their eyes may be more susceptible to pressure rises, and they face a longer potential duration of disease and treatment exposure.

The Long Game and Prognosis

TSPK is not a short-lived illness. A study tracking patients over ten years found that the average disease duration for those followed beyond a single year was about 11 years.¹⁵ Some people eventually “grow out” of the condition, with flares becoming less frequent and eventually stopping altogether. Others deal with intermittent episodes throughout their adult lives. The literature contains at least one case described as possibly the longest course on record, suggesting that extreme chronicity, while uncommon, is part of the known spectrum.¹⁰

The reassuring news is that TSPK does not typically cause lasting damage to vision. Most patients maintain visual acuity of 20/30 or better, and those who experience mild blurring during active flares generally improve with treatment.¹⁵ A case series at a major referral center similarly found that the majority had visual acuity between 20/20 and 20/30.³ So while the disease is chronic and recurrent, it is not blinding. The main long-term risk to vision comes not from the disease itself but from the medications used to treat it, particularly prolonged steroid use.

The Emotional and Practical Toll

Good visual prognosis numbers can obscure how much TSPK affects everyday life. A study that used social networks to survey patients with this rare condition found that about a fifth rated the impact on their daily activities as severe. Nearly 40% reported reduced professional activity because of their symptoms, and a striking 80% said they were deeply saddened by their eye condition.¹⁶

Those numbers are striking for a disease that preserves visual acuity. Part of the burden comes from the unpredictability: patients can never be sure when the next flare will strike, and bright-light sensitivity during active episodes makes driving, screen work, and outdoor activities uncomfortable. Part of it comes from the rarity of the diagnosis. Many patients find that their primary care doctors, and even some ophthalmologists, have never heard of the condition. Feeling unrecognized by the medical system adds a layer of frustration on top of the physical symptoms. Support communities have formed online precisely because TSPK is obscure enough that patients often feel isolated in their experience.

Refractive Surgery Considerations

If you have TSPK and are considering laser vision correction, the topic deserves a careful conversation with your surgeon. A case report documented a patient who had LASIK on one eye and PRK on the other. The TSPK recurred in the LASIK eye about ten months later but did not recur in the eye treated with PRK.¹⁷ The authors suggested that PRK may be preferable in TSPK patients, though they acknowledged that a single case is far too thin to draw firm conclusions. The thinking is that PRK removes the epithelium entirely, potentially eliminating the layer where TSPK’s lesions live, while LASIK creates a flap that leaves most of the epithelium intact.

This is admittedly one data point, and no larger study has confirmed it. But given the limited evidence, ophthalmologists who encounter TSPK patients seeking refractive surgery may lean toward surface-based procedures rather than LASIK. Anyone in this situation should make sure their surgeon is aware of the TSPK history before any procedure is planned.

Associated Conditions and Emerging Connections

Researchers have begun exploring whether TSPK travels with other immune-mediated conditions. The HLA-DR3 association mentioned earlier is shared with conditions like celiac disease and type 1 diabetes, which raises the question of whether TSPK patients have a higher rate of these autoimmune disorders. A recent case report described a patient with both TSPK and celiac disease, and the authors highlighted the overlapping HLA-DR3 link as a possible mechanistic connection.⁸ This does not mean most TSPK patients have celiac disease or vice versa. It does mean the association is biologically plausible and worth investigating in larger studies. If you have TSPK and unexplained gastrointestinal symptoms, it may be worth mentioning the possible connection to your doctor.

Because TSPK is rare, most of the published evidence consists of case reports and small case series rather than the large randomized trials that exist for more common eye diseases. That limits how confidently anyone can make sweeping recommendations about treatment algorithms, prognostic timelines, or associated conditions. The field is slowly building a more complete picture, but patients and clinicians working with TSPK today are often navigating with incomplete maps, relying on clinical experience and a patchwork of small studies to guide decisions.

1
PubMed. Thygeson Superficial Punctate Keratitis: A Clinical and Immunologic Review
2
Canadian Journal of Ophthalmology. A rare diagnosis in young eyes: clinical insights from a pediatric cohort with Thygeson’s superficial punctate keratitis
3
PubMed Central. Thygeson’s superficial punctate keratopathy: A review and case series
4
PubMed Central. Thygeson’s superficial punctate keratitis (TSPK): a paediatric case report and review of the literature
5
PubMed. Confocal microscopy of Thygeson’s superficial punctate keratopathy
6
PubMed. In vivo laser confocal microscopy findings of Thygeson superficial punctate keratitis
7
PubMed Central. The role of common viral ocular pathogens in Thygeson’s superficial punctate keratitis
8
PubMed Central. Association Between Thygeson Superficial Punctate Keratitis and Celiac Disease
9
PubMed Central. Thygeson’s superficial punctate keratitis in children
10
PubMed. Superficial punctate keratitis of thygeson: the longest course on record?
11
PubMed Central. Long-term topical cyclosporin A therapy in Thygeson’s superficial punctate keratitis: a case report
12
PubMed. Topical Tacrolimus in Thygeson Superficial Punctate Keratitis
13
The Professional Medical Journal. Efficacy and safety of topical tacrolimus 0.03% ointment in thygeson superficial punctate keratitis
14
PubMed Central. Topical Tacrolimus 0.1% in the Treatment of Thygeson’s Superficial Punctate Keratitis
15
PubMed. Thygeson’s superficial punctate keratitis: ten years’ experience
16
PubMed Central. Using pre-existing social networks to determine the burden of disease and real-life needs in rare diseases: the example of Thygeson’s superficial punctate keratitis
17
American Journal of Ophthalmology. Recurrence of Thygeson’s Superficial Punctate Keratitis After Excimer Laser Keratectomy: LASIK Versus PRK